Revolutionizing Patient Care Through Advanced Brain Monitoring and Generative AI
Fueled by prior support from the Department of Defense, Moberg Analytics has opened a seed funding round to accelerate the deployment of this transformative technology at leading pilot sites around the world.
Dick Moberg, CEO & Founder, Moberg Analytics:
"At Moberg Analytics, we've spent decades transforming raw brain data into clinically actionable insights at the bedside. By integrating generative AI, we're advancing the next frontier of precision medicine, delivering tailored, real-time decision support when seconds count. This collaboration accelerates our vision: turning complex neurophysiology into timely, personalized interventions that save lives."
Andrew Fegley, Co-Founder, NXT Humans:
"Moberg Analytics has spent years turning intricate brain signals into clear bedside insights; our job at NXT Humans is to layer in AI that flags the right pattern the moment it matters. Together we're converting mass amounts of neuro-data into clear, lifesaving actions - helping medical teams move from reactive to proactive neurocritical care. If these insights help a care team intervene even a minute sooner, that minute can save a life."
About Moberg AnalyticsMoberg Analytics is a cutting-edge, fast-growing startup located in the heart of Center City, Philadelphia. They are at the forefront of medical technology innovation, developing solutions that bring clinical decision support and precision medicine directly to the point of care. Leveraging decades of expertise in medical device connectivity, data integration, cloud technology, and AI, Moberg Analytics creates intuitive products for both civilian and military use. Funded by the U.S. Army's Department of Defense, Moberg Analytics will empower healthcare providers with the data they need for informed, life-saving decisions. Learn more about Moberg Analytics: https://moberganalytics.com/
About NXT HumansNXT Humans is an AI-native innovation agency focused on helping organizations integrate generative AI into core business operations. Founded by experts in digital strategy and machine learning, the company specializes in building custom AI tools that drive efficiency, creativity, and data-driven decision-making. NXT Humans partners with clients across industries to design and deploy intelligent systems tailored to real-world challenges. Their team brings deep technical expertise in generative and agentic AI, along with a strong focus on practical implementation. In healthcare, NXT Humans is enabling a new wave of clinical intelligence by embedding AI directly into patient care workflows. https://nxthumans.com/
For more information, please contact
Dick MobergCEO & Founder, Moberg AnalyticsEmail: info@moberganalytics.comWebsite: www.moberganalytics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/revolutionizing-patient-care-through-advanced-brain-monitoring-and-generative-ai-302516410.html
SOURCE Moberg Analytics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
a day ago
- CBS News
Autonomous planes being developed by Boston company aiming to fix pilot shortage
Most people have heard of autonomous cars. But what about autonomous planes? A Boston company is now working to put the pilotless planes in the sky. "The air is still quite dangerous, so if we can get humans out of harm's way, particularly for our [Department of Defense] customers, that's a really important mission for us," Merlin CEO & founder Matt George said. The Boston-based company develops cost-effective takeoff-to-touchdown airplanes. "Merlin is the leading developer of autonomy for very large airplanes like this! The best way to think about what we're building is a pilot, just not a human one, to enable our customers and partners to go fly their airplanes in pretty new and interesting ways including some, eventually, uncrewed stuff in the future," George said. Inside the Merlin Pilots lab on South Street in Boston, folks are busy developing new state-of-the-art technology that takes the skills of a human pilot and translates them into AI software. George said the goal is to help tackle the pilot shortage in America. "The Air Force is our largest customer, they're short about 2,000 pilots a year of seats that they wish they can fill but can't fill. And now we're transitioning in the age where autonomy and AI is going to play a really important part in aviation and in aviation safety and allowing folks to use the sky in some new and novel ways," George said. They have 170 employees working at the frontier of aviation and are proud to be here in Boston. "Historically Boston was the tech hub. So, I'm really proud of the fact that we're starting to bring some of these frontiers, really hard technologies both in biotech, in aerospace and nuclear with Commonwealth Fusion back to Boston," George said. So with all this high tech does not mean you will go to Logan and see any autonomous planes anytime soon. In fact, George said there's no telling when folks will come to the airport and board a plane without a pilot. "I wouldn't put a number on it. I am certainly not betting on showing up to my Delta or American Airlines flight and seeing nobody aboard the flight deck. Human pilots are still a really important part of that future. We're just bringing autonomy in to augment those folks," said George.
Business Wire
a day ago
- Business Wire
Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense's premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation in support of warfighter health and readiness. Direct Access to DoD Decision-Makers and Researchers MHSRS provides direct access to organizations seeking military partnerships and connects companies with key funding organizations. Tivic's President of Biopharma and Chief Operating Officer, Michael Handley, met with key members of the Biomedical Advanced Research and Development Authority (BARDA), the Armed Forces Radiobiology Research Institute (AFRRI) and the Medical CBRN Defense Consortium (MCDC) to discuss potential pathways to deploy Entolimod as a military countermeasure. BARDA's mission is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. AFRRI's mission is to defend the Nation from nuclear and radiological threats through research, leadership, training, and education. The MCDC was formed in response to the US Government's expressed interest to engage and fund advanced development efforts to support the Department of Defense's (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel. 'It was an honor to contribute to the vital conversations that were focused generally on radiation medical countermeasures, and specifically on our lead clinical product candidate, Entolimod, which has the potential to protect the warfighter in the instance that they are exposed to radiation,' said Handley. Representatives from Tivic joined global thought leaders, military leaders and researchers to share insights, explore collaborative opportunities, and present ongoing research intended to improve health outcomes for warfighters exposed to radiation in the field. About MHSRS MHSRS serves as a dynamic platform for the exchange of research findings across multiple disciplines, including combat casualty care, medical countermeasures, infectious disease, and mental health. The symposium fosters collaboration among business leaders, scientists, clinicians, and policymakers, ensuring innovations reach those who serve as quickly and effectively as possible. About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities, as well as interactions with governmental agencies, such as BARDA, the AFRRI and the MCDC; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Boston Globe
2 days ago
- Boston Globe
Aviation startup Merlin Labs valued at $800 million in deal to go public
Advertisement Last year, the company landed a $105 million contract with the Department of Defense to integrate Merlin Pilot software into the C-130J airlifter manufactured by Lockheed Martin. Inflection Point chief executive Mike Blitzer will join the Merlin board as a result of the upcoming deal; Inflection Point's recent successes include two other companies launched through similar SPAC deals, USA Rare Earth (current market cap of $1.7 billion) and Intuitive Machines (worth $1.6 billion today). Jon Chesto can be reached at
